Biophan CEO Michael Weiner Discusses Company's Proprietary Biomedical Solutions in New TV Program by WallStreetCast; Provides In-Depth Discussion of the Biophan Story.

ROCHESTER, N.Y. -- Biophan Technologies, Inc. (OTCBB:BIPH), a developer of next-generation medical technology, has announced the online availability of an appearance by CEO Michael Weiner, on the new cable TV program, produced by WallStreetCast, which aired nationally on cable television on June 9th.

The program is produced by WallStreetCast in conjunction with The Money Channel. The host, Steve Crowley, is the former Money Editor for both ABC-TV ("Good Morning America") and the syndicated feature, "MoneyPro News."

In the interview, Mr. Weiner discusses Biophan's proprietary biomedical and broad intellectual property portfolio in nanotechnology and other cutting-edge areas of medical device technology in a number of multi-billion-dollar biomedical marketplaces.

During the segment, a physician describes some of the dangers of MRI for patients with implanted medical devices.

Mr. Weiner also discusses Biophan technologies for imaging the inside of implanted vascular stents. Today, diagnosis of stent blockage typically requires use of x-rays and potentially toxic contrast agents. Biophan is developing multiple approaches to permit non-invasive MRI imaging of the interior of stents by eliminating the image blockage caused by the stent itself.

The program can be viewed free of charge in streaming media format by visiting http://www.biophan.com/wallstreetcast1.html. A media player will launch automatically.

About WallStreetCast

WallStreetCast profiles and showcases proven investing strategies, money managers and the CEOs of select public companies whose stocks trade on the AMEX and NASDAQ, including special situation OTCBB stocks. This program utilizes award-winning network producers and high-quality content. To learn more about WallStreetCast, please visit http://www.moneychannel.tv/about_us.htm.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 127 U.S. patents, licenses, or applications. This total includes 37 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 82 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.